If you're interested in adding some exposure to the small side of the market to your portfolio then you might want to take a look at the shares listed below.
Here's why these ASX small caps have been tipped as buys:
Image source: Getty Images
Bigtincan Holdings Ltd (ASX: BTH)
Bigtincan is an artificial intelligence-powered sales enablement automation platform provider. Among the growing number of blue chips using its platform are 7 of the top 10 companies on the Fortune 500. Bigtincan has been growing very quickly in recent years and looks well-placed to continue this trend in FY 2021 following a very strong half year result last month. At the end of the half, its annualised recurring revenue (ARR) stood at $48.4 million. This was a 50% increase over the prior corresponding period.
Analysts at Ord Minnett are positive on its prospects. They currently have a buy rating and $1.08 price target on its shares.
Doctor Care Anywhere Ltd (ASX: DOC)
Doctor Care Anywhere is a growing UK-based telehealth company. It is aiming to deliver high-quality, effective, and efficient care to its patients, while reducing the overall cost of providing clinical services. Thanks to the growing popularity of telehealth, Doctor Care Anywhere has been growing quickly. For example, in January it released its fourth quarter update and revealed a 151% increase in revenue to 3.8 million pounds.
Bell Potter is a fan of the company. It has a buy rating and $1.95 price target on the company's shares.
Universal Store Holdings Limited (ASX: UNI)
Universal Store is a fashion retailer with a growing network of stores across Australia. It has been performing positively during the pandemic and recently released a very strong half year result. For the six months ended 31 December, Universal Store delivered a 23.3% increase in sales to $118 million and a 63.6% increase in underlying net profit after tax to $21.1 million. This was driven by strong online and like for like store growth. Pleasingly, management is confident this strong form will continue in the second half.
Morgans is positive on the company and has put an add rating and $8.37 price target on its shares.
